A gathering of minds! 🧠 This week, we met with the Alzheimer's Research UK Drug Discovery Institutes Oxford, Cambridge, and UCL to discuss the bioinformatics challenges and opportunities for enhancing our identification and prioritisation of targets in the context of neurodegeneration — ultimately with the aim of developing new drugs for patients Thank you to those who attended for the excellent discussions!
Open Targets
Research
Hinxton, Cambs 6,199 followers
A partnership using human genetics and genomics data for systematic drug target identification and prioritisation.
About us
Open Targets is an innovative, large-scale, multi-year, public-private partnership that uses human genetics and genomics data for systematic drug target identification and prioritisation. Open Targets brings together complimentary expertise of our academic and industry partners, Bristol Myers Squibb, EMBL-EBI, Genentech, GSK, Pfizer, Wellcome Sanger Institute, and Sanofi. The freely available Open Targets Platform (platform.opentargets.org) makes it easy for researchers working in many disciplines to identify and prioritise therapeutic targets for new medicines. Open Targets Genetics (genetics.opentargets.org), is our portal for investigation of Genome Wide Association Study (GWAS) data to assist in identifying the causal genes to prioritise drug targets. The portal aggregates and merges genetic associations curated from literature and newly-derived loci from UK Biobank andn FinnGen with (open source) functional genomics data including epigenetics (e.g., chromatin conformation, chromatin interactions) and quantitative trait loci (e.g., eQTLs from GTEX, pQTL), and applies statistical fine-mapping across thousands of trait-associated loci, to resolve association signals and link each variant to its proximal and distal target gene(s), using a single evidence score. Open Targets complements data integration with large scale systematic experimental approaches to support target identification, prioritisation and validation, and is committed to sharing its data openly with the scientific community.
- Website
-
http://www.opentargets.org
External link for Open Targets
- Industry
- Research
- Company size
- 201-500 employees
- Headquarters
- Hinxton, Cambs
- Type
- Partnership
- Founded
- 2014
- Specialties
- Bioinformatics, Target identification, Genetics, Genomics, and Target prioritisation
Locations
-
Primary
Get directions
Wellcome Genome Campus
Hinxton, Cambs CB10 1SD, GB
Employees at Open Targets
-
Ian Dunham
Formerly Director at Open Targets
-
Gosia Trynka
Science Director at Open Targets and Group Leader at Sanger Institute
-
David Ochoa
Target discovery | Computational Biology | Human Disease Genetics | ML | Cloud computing
-
Emmanouil Athanasiadis
Assistant Professor in Computational Biology and Medical Informatics at University of West Attica (GR) and Visiting Scientist at Open Targets…
Updates
-
A little zen for your timeline... A plane from the Duxford Airfield flying over the Wellcome Genome Campus 🛩️
-
Open Targets Scientific Director Gosia Trynka shared her thoughts on how AI is changing immunology research as part of Immunity's Voices, with a focus on integration and collaboration Gosia is a group leader at the Wellcome Sanger Institute and leads several Open Targets projects 👩🔬
-
-
Welcome to the team Tobi Alegbe and Vivien H.! 👋 Tobi joins the team as a Single Cell Data Scientist, working to expand our informatics platforms through the integration of single cell omics data. Vivien is a bioinformatician in the data team, actively developing our pipelines to analyse, interpret and integrate our growing experimental research data with public domain data.
-
-
The poll is now closed! (but we still want to hear from you in the comments!) This input from the community is key information for our Product Manager Annalisa Buniello: "Thank you all for contributing to our scientific roadmaps! Given the interest in single-cell datasets that can shed some light on cell type function in disease, these will be a priority for analysis and integration into the Open Targets informatics ecosystem. Our initial focus will be on IBD, lung cancer, and neurodegenerative diseases. Exciting science ahead: watch this space!"
📊 What is the most important question we should address from single-cell data? Our latest Integration day was a chance to reflect on some of the recent work we've done using single-cell sequencing, and think about potential future work in this space. What do you think?
This content isn’t available here
Access this content and more in the LinkedIn app
-
Open Targets reposted this
⏰ 11 days left to apply for the #Biocurator role in my team, leading efforts to curate human gene, variant, and expression perturbation data to build the Open Targets Perturbation Catalogue! More details and how to apply here 👉 https://lnkd.in/ea9z9pBS
Meet Mallory Freeberg, a maths and powerlifting whiz, and our new Team Leader for Human Genomics. Mallory’s curiosity and love of maths led to her becoming the first student at her university to major in bioinformatics. Mallory is now leading the variation and regulations teams for the Ensembl genome browser, our world-leading resource for comparative genomics, evolution, sequence variation, and transcriptional regulation. Mallory's team also manages: 1️⃣ DECIPHER project, which aids clinical genome variation interpretation 2️⃣ Ensembl Variant Effect Predictor (VEP) tool, which determines the effects of genetic variants on genes 3️⃣ Gene2Phenotype platform, which aids diagnostic variant filtering In her new role, Mallory sees herself as a community builder, enabling her team to advance the resources and tools they manage, leverage new technologies, and build connections with the wider research and clinical communities. https://lnkd.in/ggAnSZwH #bioinformatics #genomics #geneticvariation #leadership
-
-
Did you know the EMBL-EBI Training website has recorded webinars and tutorials to get you started with the Open Targets informatics tools? 👩🎓 Is there other training you'd like to see? Let us know!
-
-
📊 What is the most important question we should address from single-cell data? Our latest Integration day was a chance to reflect on some of the recent work we've done using single-cell sequencing, and think about potential future work in this space. What do you think?
This content isn’t available here
Access this content and more in the LinkedIn app